37 to 42 of 150 results
For the first time in the Netherlands, a patient with a serious autoimmune disease has been treated with CAR-T cell therapy. With this, the LUMC has achieved an important medical milestone in the development of innovative treatments outside of oncology.
Read more about Medical milestone: CAR-T used to treat autoimmune disease
Another major scientific breakthrough has been achieved in the Leiden region. Together, Mimetas and the Leiden Academic Centre for Drug Research (LACDR) have developed an advanced "artery-on-a-chip" model.
Three research teams from Leiden University have recently been awarded prestigious NWO grants. The funding will enable groundbreaking fundamental research in areas such as drug development and cosmic particles.
Researchers at the LACDR at LUMC have developed a synthetic alternative to antibodies that is more stable, cheaper and easier to produce. This discovery could radically change the future of drug development and administration.
Read more about Artificial “antibodies”: the future of drug development?
Researchers at LUMC have used advanced RNA analysis techniques to discover new biomarkers for the muscle disease FSHD. These biomarkers offer opportunities for better diagnostics and more targeted treatments.
The LUMC introduces PERISCOPE, an AI model that assesses the risk of infection in patients who have recently undergone surgery. By identifying risks more quickly, healthcare providers can intervene earlier and better prevent complications.
Read more about LUMC uses AI to predict infections after surgery
